Hantech Bio-Technology Co., Ltd. (TPEX:1294)
Taiwan · Delayed Price · Currency is TWD 55.70
-1.10 (-1.94%)
Aug 20, 2026, 1:30 PM CST
Hantech Bio-Technology Ratios and Metrics
Market cap in millions TWD. Fiscal year is January - December.
Millions TWD. Fiscal year is Jan - Dec.
Total Valuation
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 19, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 2,023 | 2,382 | 2,572 | 2,024 | 816 | - | |
Market Cap Growth | -18.85% | -7.40% | 27.10% | 148.03% | - | - |
Enterprise Value | 1,760 | 2,211 | 2,421 | 2,016 | 858 | - |
Last Close Price | 55.70 | 63.18 | 64.99 | 55.83 | 22.65 | - |
Price Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 19, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
PE Ratio | 13.71 | 17.13 | 16.52 | 13.66 | 17.19 | - |
Forward PE | - | 10.46 | 12.84 | - | - | - |
PS Ratio | 2.34 | 3.06 | 3.44 | 3.24 | 2.70 | - |
PB Ratio | 2.46 | 2.86 | 3.13 | 5.04 | 3.04 | - |
P/TBV Ratio | 2.48 | 2.89 | 3.17 | 5.13 | 3.07 | - |
P/FCF Ratio | 16.74 | 16.41 | 20.40 | - | - | - |
P/OCF Ratio | 13.29 | 14.83 | 17.06 | 10.55 | 12.92 | - |
EV Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 19, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
EV/Sales Ratio | 2.04 | 2.84 | 3.24 | 3.23 | 2.84 | - |
EV/EBITDA Ratio | 8.02 | 10.99 | 10.95 | 10.17 | 12.52 | - |
EV/EBIT Ratio | 9.58 | 12.78 | 12.26 | 10.86 | 15.10 | - |
EV/FCF Ratio | 14.56 | 15.23 | 19.20 | - | - | - |
Financial Efficiency
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 19, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Debt / Equity Ratio | 0.13 | 0.14 | 0.19 | 0.82 | 0.44 | 0.81 |
Debt / EBITDA Ratio | 0.49 | 0.54 | 0.70 | 1.61 | 1.57 | 2.50 |
Debt / FCF Ratio | 0.89 | 0.78 | 1.26 | - | - | - |
Net Debt / Equity Ratio | -0.32 | -0.27 | -0.27 | 0.41 | 0.16 | 0.33 |
Net Debt / EBITDA Ratio | -1.25 | -1.12 | -1.01 | 0.82 | 0.64 | 1.15 |
Net Debt / FCF Ratio | -2.21 | -1.56 | -1.77 | -1.60 | -2.22 | -1.67 |
Asset Turnover | 0.71 | 0.68 | 0.73 | 0.89 | 0.71 | 0.70 |
Inventory Turnover | 5.33 | 5.37 | 5.87 | 6.27 | 6.85 | 6.66 |
Quick Ratio | 1.63 | 1.93 | 2.41 | 1.14 | 1.29 | 1.65 |
Current Ratio | 2.00 | 2.40 | 2.78 | 1.52 | 1.64 | 2.01 |
Return on Equity (ROE) | 18.35% | 16.83% | 25.43% | 44.04% | 20.54% | 19.11% |
Return on Assets (ROA) | 9.45% | 9.46% | 12.04% | 16.53% | 8.37% | 7.23% |
Return on Invested Capital (ROIC) | 24.82% | 23.11% | 27.14% | 33.86% | 16.46% | 16.34% |
Return on Capital Employed (ROCE) | 20.20% | 18.80% | 21.30% | 26.30% | 15.10% | 12.90% |
Yields
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 19, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Earnings Yield | 7.37% | 5.84% | 6.05% | 7.32% | 5.82% | - |
FCF Yield | 5.97% | 6.09% | 4.90% | -5.04% | -2.41% | - |
Dividend Yield | 4.46% | 3.96% | 4.10% | 1.04% | 2.23% | - |
Payout Ratio | 58.63% | 62.88% | 12.47% | 11.37% | - | 24.75% |
Buyback Yield / Dilution | -1.32% | -4.91% | -3.19% | -8.45% | -7.98% | -2.60% |
Total Shareholder Return | 3.14% | -0.96% | 0.91% | -7.41% | -5.74% | -2.60% |